Collectively, these human data suggest that point mutations in the pseudokinase domain of JAK1 are critical to pathological processes, similarly to the well-known JAK2 V617F mutation found in polycythaemia vera, myelofibrosis, and essential thrombocythemia (23). This evidence concerns the gene JAK2 and acquired polycythemia vera.